Two Caribbean Manufacturing Platforms, Two Very Different Profiles

Puerto Rico and the Dominican Republic are the two largest manufacturing economies in the Caribbean, separated by 80 miles of ocean and by a vast difference in regulatory framework, labor cost structure, and target industry profile. Puerto Rico, as a U.S. territory, operates under full U.S. federal regulatory jurisdiction, including FDA oversight identical to any U.S. state, OSHA workplace standards, EPA environmental requirements, and U.S. minimum wage law. The Dominican Republic operates as a sovereign nation with its own regulatory framework, trade relationships, and investment incentive structure.

The comparison between the two platforms is most relevant for pharmaceutical and medical device companies, which must navigate FDA oversight regardless of manufacturing location and therefore face a different regulatory cost structure in PR versus the DR. For other manufacturing categories, the comparison is less direct, as Puerto Rico’s manufacturing sector is overwhelmingly dominated by high-value pharmaceuticals and medical devices that require the full U.S. regulatory environment, while the DR’s free zone economy spans a broader range of products including apparel, tobacco, electronics assembly, and consumer goods.

Tax Incentive Comparison

Puerto Rico’s Act 60 (2019 Industrial Incentive Code, consolidating prior Acts 73, 20, 22, and related legislation) provides manufacturing entities with a reduced corporate income tax rate of 4% on eligible manufacturing income, a 12% withholding tax on dividends (reduced from federal rates through Act 60 provisions), and a special 90% tax exemption on municipal taxes. Act 60 benefits apply to Puerto Rico-source manufacturing income and require the business to maintain genuine operations and employment on the island. For pharmaceutical companies already planning for a fully-staffed, FDA-compliant Puerto Rico facility, Act 60’s 4% rate is a significant advantage over the U.S. federal statutory corporate rate of 21%.

The Dominican Republic’s Law 8-90 free zone regime provides a zero percent corporate income tax rate for 15-20 years, zero import duties on inputs and capital equipment, zero export taxes, and exemption from municipal and transfer taxes. For the comparison period, Law 8-90’s zero rate is arithmetically more favorable than Puerto Rico’s 4% Act 60 rate. However, the comparison must account for the fact that Puerto Rico’s Act 60 benefits apply within the full U.S. regulatory and currency framework, while the DR’s Law 8-90 benefits require operating under Dominican regulatory jurisdiction and absorbing the costs associated with establishing FDA compliance from a non-U.S. territory.

Labor Cost: The Central Differentiator

Labor cost is where the two platforms diverge most dramatically. Puerto Rico’s manufacturing sector is subject to U.S. federal minimum wage law (currently $7.25/hr, though PR has been exempt from certain recent increases) and operates in a labor market where pharmaceutical production workers earn $28-38/hr including benefits, FDA-experienced quality managers command $85,000-130,000 annually, and GMP-trained engineers typically earn $70,000-110,000/year. These wages reflect both the high skill requirements of pharmaceutical production and Puerto Rico’s high cost of living relative to mainland Caribbean alternatives.

The Dominican Republic’s free zone pharmaceutical sector labor costs, by EGS estimate, run $2.50-3.40/hr for production workers, $800-1,400/month for quality control analysts, and $1,500-3,500/month for pharmaceutical managers. The 8-12x labor cost differential between the two platforms is the primary driver of why DR-based pharmaceutical manufacturing is economically viable for products where FDA compliance can be maintained at lower total cost: generic solid oral dosage forms, OTC topicals, nutritional supplements, and other established-pathway products where the regulatory overhead per unit is manageable.

For complex biologics, novel drug delivery systems, or first-in-class products requiring dense FDA interaction and frequent agency inspections, Puerto Rico’s advantages in FDA-experienced workforce depth, regulatory precedent, and proximity to U.S. legal and regulatory infrastructure often justify the labor premium. Puerto Rico hosts approximately 90 FDA-regulated pharmaceutical manufacturing facilities and has a resident workforce of several thousand FDA-experienced pharmaceutical professionals, representing an institutional depth the DR cannot yet match.

FDA Compliance Cost: PR vs. DR

FDA compliance costs are structurally higher in the Dominican Republic than in Puerto Rico, for reasons that have nothing to do with regulatory standards (which are identical) and everything to do with ecosystem depth. In Puerto Rico, FDA-experienced consultants, analytical testing laboratories, validation specialists, and regulatory affairs firms are abundant, competitive, and physically proximate. FDA inspectors based in the San Juan District Office conduct routine inspections with relatively short travel logistics. The island’s deep FDA compliance ecosystem allows Puerto Rico-based manufacturers to resolve compliance issues quickly with minimal production disruption.

In the Dominican Republic, FDA-experienced compliance resources are sparser and more expensive per engagement, as many must be flown in from the U.S. mainland or Puerto Rico. FDA inspections originating from the FDA Latin America offices involve more complex logistics and scheduling. New DR-based pharmaceutical operators should budget for U.S.-based consulting and validation support during their initial establishment period, typically at $300-500/hr for specialist consultants, and plan for longer compliance issue resolution timelines than they would experience in Puerto Rico.

Which Platform Fits Which Company Profile

Puerto Rico is the right platform for pharmaceutical companies producing high-value, complex products where the FDA workforce ecosystem, U.S. legal jurisdiction, no currency risk, and regulatory precedent justify the labor premium. Products with unit values above $50-100 (branded generics, specialty drugs, complex injectables, biologics) can typically absorb Puerto Rico’s higher production cost within acceptable margin structures. Companies already operating Puerto Rico facilities that are evaluating capacity expansion should weigh the incremental Act 60 benefits against the startup cost of establishing a parallel DR manufacturing site.

The Dominican Republic is the right platform for pharmaceutical companies producing lower-margin generics, OTC products, nutritional supplements, or established-pathway medications where labor cost drives competitive unit economics. Companies pursuing PEPFAR or USAID institutional supply programs targeting the Caribbean and Latin American markets, where price competition is intense, may find the DR’s cost structure necessary to submit competitive bids. The Caribbean Economic Corridor model that EGS supports is specifically designed to make DR-based manufacturing viable for these product categories by providing the regulatory, logistics, and compliance infrastructure that reduces the operational premium of manufacturing in a non-U.S. territory.

• DR Pharmaceutical Manufacturing: FDA GMP Guide
• DR Medical Device Manufacturing: FDA Guide
• Dominican Republic Law 8-90 Free Zone Guide